Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain

REFERENCES

1. 1.↵
   1. Garcia-Romeu A,
   2. Davis AK,
   3. Erowid F, et al

   . Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 2019;33:1088–101 doi:10.1177/0269881119845793

   CrossRef
2. 2.↵
   1. Goodwin GM,
   2. Aaronson ST,
   3. Alvarez O, et al

   . Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022;387:1637–48 doi:10.1056/NEJMoa2206443

   CrossRef
3. 3.↵
   1. Krediet E,
   2. Bostoen T,
   3. Breeksema J, et al

   . Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol 2020;23:385–400 doi:10.1093/ijnp/pyaa018

   CrossRef
4. 4.↵
   1. Schultes RE,
   2. Hofmann A

   . Plants of the gods: their sacred, healing, and hallucinogenic powers. New York: McGraw-Hill, 1992
5. 5.↵
   1. Akers BP,
   2. Ruiz JF,
   3. Piper A, et al

   . A prehistoric mural in Spain depicting neurotropic psilocybe mushrooms? Econ Bot 2011;65:121–28 doi:10.1007/s12231-011-9152-5

   CrossRef
6. 6.↵
   1. Bruhn JG,
   2. Smet PA,
   3. El-Seedi HR, et al

   . Mescaline use for 5700 years. Lancet 2002;359:1866 pmid:12044415

   PubMed
7. 7.↵
   1. Brenan JP,
   2. Schultes RE,
   3. Hofmann A

   . Plants of the gods: origins of hallucinogenic use. Kew Bull 1980;35
8. 8.↵
   1. Passie T,
   2. Seifert J,
   3. Schneider U, et al

   . The pharmacology of psilocybin. Addict Biol 2002;7:357–64 doi:10.1080/1355621021000005937 pmid:14578010

   CrossRefPubMed
9. 9.↵
   1. Hofmann A

   . How LSD originated. J Psychoactive Drugs 1979;11
10. 10.↵
    1. Holmstedt B,
    2. Lindgren JE,
    3. Plowman T, et al

    . Indole alkaloids in Amazonian Myristicaceae: Field and laboratory research. Bot Mus Lealf Harv Univ 1980;28
11. 11.↵
    1. Saavedra JM,
    2. Axelrod J

    . Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science 1972;175:1365–66 doi:10.1126/science.175.4028.1365 pmid:5059565

    CrossRefPubMed
12. 12.↵
    1. Smigielski L,
    2. Kometer M,
    3. Scheidegger M, et al

    . Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep 2019;9:14914 doi:10.1038/s41598-019-50612-3 pmid:31649304

    CrossRefPubMed
13. 13.↵
    1. Kwan AC,
    2. Olson DE,
    3. Preller KH, et al

    . The neural basis of psychedelic action. Nat Neurosci 2022;25:1407–19 doi:10.1038/s41593-022-01177-4 pmid:36280799

    CrossRefPubMed
14. 14.↵
    1. Shao LX,
    2. Liao C,
    3. Gregg I, et al

    . Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021;109:2535–44.e4 doi:10.1016/j.neuron.2021.06.008 pmid:34228959

    CrossRefPubMed
15. 15.↵
    1. Hesselgrave N,
    2. Troppoli TA,
    3. Wulff AB, et al

    . Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 2021;118:e2022489118 doi:10.1073/pnas.2022489118 pmid:33850049

    CrossRefPubMed
16. 16.↵
    1. Strassman RJ

    . Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73:121–24 doi:10.1016/0166-4328(96)00081-2 pmid:8788488

    CrossRefPubMed
17. 17.↵
    1. Pilecki B,
    2. Luoma JB,
    3. Bathje GJ, et al

    . Ethical and legal issues in psychedelic harm reduction and integration therapy. Background information on psychedelic therapy, harm reduction, and integration. Harm Reduct J 2020;18:40 doi:10.1186/s12954-021-00489-1 pmid:33827588

    CrossRefPubMed
18. 18.↵
    1. Studerus E,
    2. Kometer M,
    3. Hasler F, et al

    . Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 2011;25:1434–52 doi:10.1177/0269881110382466

    CrossRef
19. 19.↵
    1. Madsen MK,
    2. Fisher PM,
    3. Stenbæk DS, et al

    . A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol 2020;33:71–80 doi:10.1016/j.euroneuro.2020.02.001 pmid:32146028

    CrossRefPubMed
20. 20.↵
    1. Pochettino ML,
    2. Cortella AR,
    3. Ruiz M

    . Hallucinogenic snuff from northwestern Argentina: microscopical identification of Anadenanthera colubrina var. cebil (Fabaceae) in powdered archaeological material. Econ Bot 1999;53:127–32 doi:10.1007/BF02866491

    CrossRef
21. 21.↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al

    . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71 doi:10.1136/bmj.n71 pmid:33782057

    CrossRefPubMed
22. 22.↵
    1. Portnow LH,
    2. Vaillancourt DE,
    3. Okun MS

    . The history of cerebral PET scanning: from physiology to cutting-edge technology. Neurology 2013;80:952–56 doi:10.1212/WNL.0b013e318285c135 pmid:23460618

    CrossRefPubMed
23. 23.↵
    1. Dale AM,
    2. Halgren E

    . Spatiotemporal mapping of brain activity by integration of multiple imaging modalities. Curr Opin Neurobiol 2001;11:202–08 doi:10.1016/s0959-4388(00)00197-5 pmid:11301240

    CrossRefPubMed
24. 24.↵
    1. McCulloch DE,
    2. Madsen MK,
    3. Stenbæk DS, et al

    . Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol 2022;36:74–84 doi:10.1177/02698811211026454

    CrossRef
25. 25.↵
    1. Smigielski L,
    2. Scheidegger M,
    3. Kometer M, et al

    . Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage 2019;196:207–15 doi:10.1016/j.neuroimage.2019.04.009 pmid:30965131

    CrossRefPubMed
26. 26.↵
    1. Tompson S,
    2. Chua HF,
    3. Kitayama S

    . Connectivity between mPFC and PCC predicts post-choice attitude change: the self-referential processing hypothesis of choice justification. Hum Brain Mapp 2016;37:3810–20 doi:10.1002/hbm.23277 pmid:27237098

    CrossRefPubMed
27. 27.↵
    1. Catlow BJ,
    2. Song S,
    3. Paredes DA, et al

    . Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 2013;228:481–91 doi:10.1007/s00221-013-3579-0 pmid:23727882

    CrossRefPubMed
28. 28.↵
    1. Kraehenmann R,
    2. Preller KH,
    3. Scheidegger M, et al

    . Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 2015;78:572–81 doi:10.1016/j.biopsych.2014.04.010 pmid:24882567

    CrossRefPubMed
29. 29.↵
    1. Kraehenmann R,
    2. Schmidt A,
    3. Friston K, et al

    . The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin 2016;11:53–60
30. 30.↵
    1. Grimm O,
    2. Kraehenmann R,
    3. Preller KH, et al

    . Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol 2018;28:691–700 doi:10.1016/j.euroneuro.2018.03.016

    CrossRef
31. 31.↵
    1. Barrett FS,
    2. Doss MK,
    3. Sepeda ND, et al

    . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 2020;10:2214 doi:10.1038/s41598-020-59282-y pmid:32042038

    CrossRefPubMed
32. 32.↵
    1. Tagliazucchi E,
    2. Carhart-Harris R,
    3. Leech R, et al

    . Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 2014;35:5442–56
33. 33.↵
    1. Carhart-Harris RL,
    2. Erritzoe D,
    3. Williams T, et al

    . Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109:2138–43 doi:10.1073/pnas.1119598109 pmid:22308440

    CrossRefPubMed
34. 34.↵
    1. Roseman L,
    2. Leech R,
    3. Feilding A, et al

    . The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci 2014;8:204 doi:10.3389/fnhum.2014.00204 pmid:24904346

    CrossRefPubMed
35. 35.↵
    1. Greicius MD,
    2. Flores BH,
    3. Menon V, et al

    . Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry 2007;62:429–37 doi:10.1016/j.biopsych.2006.09.020 pmid:17210143

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Andrews-Hanna JR,
    2. Reidler JS,
    3. Sepulcre J, et al

    . Functional-anatomic fractionation of the brain’s default network. Neuron 2010;65:550–62 doi:10.1016/j.neuron.2010.02.005

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Preller KH,
    2. Pokorny T,
    3. Hock A, et al

    . Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A 2016;113:5119–24 pmid:27091970

    PubMed
38. 38.↵
    1. Lebedev AV,
    2. Lövdén M,
    3. Rosenthal G, et al

    . Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 2015;36:3137–53 doi:10.1002/hbm.22833 pmid:26010878

    CrossRefPubMed
39. 39.↵
    1. Carhart-Harris RL,
    2. Leech R,
    3. Erritzoe D, et al

    . Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull 2013;39:1343–51
40. 40.↵
    1. Mason NL,
    2. Kuypers KP,
    3. Müller F, et al

    . Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology 2020;45:2003–11 doi:10.1038/s41386-020-0718-8 pmid:32446245

    CrossRefPubMed
41. 41.↵
    1. Madsen MK,
    2. Stenbæk DS,
    3. Arvidsson A, et al

    . Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur Neuropsychopharmacol 2021;50:121–32 doi:10.1016/j.euroneuro.2021.06.001 pmid:34246868

    CrossRefPubMed
42. 42.↵
    1. Preller KH,
    2. Duerler P,
    3. Burt JB, et al

    . Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry 2020;88:197–207
43. 43.↵
    1. Barrett FS,
    2. Krimmel SR,
    3. Griffiths R, et al

    . Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage 2020;218:116980 doi:10.1016/j.neuroimage.2020.116980 pmid:32454209

    CrossRefPubMed
44. 44.↵
    1. Carhart-Harris RL,
    2. Leech R,
    3. Hellyer PJ, et al

    . The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014;8:20 doi:10.3389/fnhum.2014.00020 pmid:24550805

    CrossRefPubMed
45. 45.↵
    1. Felix M,
    2. Stefan B

    . Acute effects of lysergic acid diethylamide (LSD) on resting brain function. Swiss Med Wkly 2019;149:w20124
46. 46.↵
    1. Müller F,
    2. Lenz C,
    3. Dolder P, et al

    . Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand 2017;136:648–57 doi:10.1111/acps.12818 pmid:28940312

    CrossRefPubMed
47. 47.↵
    1. Tagliazucchi E,
    2. Roseman L,
    3. Kaelen M, et al

    . Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 2016;26:1043–50 doi:10.1016/j.cub.2016.02.010

    CrossRef
48. 48.↵
    1. Preller KH,
    2. Burt JB,
    3. Ji JL, et al

    . Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife 2018;7:e35082 doi:10.7554/eLife.35082

    CrossRef
49. 49.↵
    1. Avram M,
    2. Müller F,
    3. Preller KH, et al

    . Effective-connectivity of thalamocortical interactions following D-amphetamine, LSD, and MDMA administration. Biol Psychiatry Cogn Neurosci Neuroimaging https://doi.org/10.1016/J.BPSC.2023.07.010 doi:10.1016/j.bpsc.2023.07.010

    CrossRef
50. 50.↵
    1. Carhart-Harris RL,
    2. Muthukumaraswamy S,
    3. Roseman L, et al

    . Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 2016;113:4853–58 pmid:27071089

    PubMed
51. 51.↵
    1. Moujaes FF,
    2. Rieser NM,
    3. Phillips C, et al

    . Comparing neural correlates of consciousness: from psychedelics to hypnosis and meditation. Biol Psychiatry Cogn Neurosci Neuroimaging https://doi.org/10.1016/J.BPSC.2023.07.003 doi:10.1016/j.bpsc.2023.07.003

    CrossRef
52. 52.↵
    1. Delli Pizzi S,
    2. Chiacchiaretta P,
    3. Sestieri C, et al

    . Spatial correspondence of LSD-induced variations on brain functioning at rest with serotonin receptor expression. Biol Psychiatry Cogn Neurosci Neuroimaging 2023;8:768–76 doi:10.1016/j.bpsc.2023.03.009 pmid:37003409

    CrossRefPubMed
53. 53.↵
    1. Timmermann C,
    2. Roseman L,
    3. Haridas S, et al

    . Human brain effects of DMT assessed via EEG-fMRI. Proc Natl Acad Sci U S A 2023;120:e2218949120 doi:10.1073/pnas.2218949120 pmid:36940333

    CrossRefPubMed
54. 54.↵
    1. Gaddis A,
    2. Lidstone DE,
    3. Nebel MB, et al

    . Psilocybin induces spatially constrained alterations in thalamic functional organization and connectivity. Neuroimage 2022;274:120130 doi:10.1016/j.neuroimage.2022.119434 pmid:35792293

    CrossRefPubMed
55. 55.↵
    1. Avram M,
    2. Müller F,
    3. Rogg H, et al

    . Characterizing thalamocortical (dys)connectivity following D-amphetamine, LSD, and MDMA administration. Biol Psychiatry Cogn Neurosci Neuroimaging 2022;7:885–94 doi:10.1016/j.bpsc.2022.04.003 pmid:35500840

    CrossRefPubMed
56. 56.↵
    1. Mueller F,
    2. Lenz C,
    3. Dolder PC, et al

    . Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry 2017;7:e1084 doi:10.1038/tp.2017.54 pmid:28375205

    CrossRefPubMed
57. 57.↵
    1. Bershad AK,
    2. Preller KH,
    3. Lee R, et al

    . Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging 2020;5:461–67 doi:10.1016/j.bpsc.2019.12.007 pmid:32033922

    CrossRefPubMed
58. 58.↵
    1. Bedford P,
    2. Hauke DJ,
    3. Wang Z, et al

    . The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. Neuropsychopharmacology 2023;48:1175–83 doi:10.1038/s41386-023-01574-8 pmid:37185950

    CrossRefPubMed
59. 59.↵
    1. Ettrup A,
    2. Svarer C,
    3. McMahon B, et al

    . Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin. Neuroimage 2016;130:167–74 doi:10.1016/j.neuroimage.2016.02.001 pmid:26876490

    CrossRefPubMed
60. 60.↵
    1. Hasler F,
    2. Quednow BB,
    3. Treyer V, et al

    . Role of prefrontal serotonin-2A receptors in self-experience during psilocybin induced altered states. Neuropsychobiology 2009;59:S60
61. 61.↵
    1. Cumming P,
    2. Scheidegger M,
    3. Dornbierer D, et al

    . Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules 2021;26:2451 doi:10.3390/molecules26092451

    CrossRef
62. 62.↵
    1. Vollenweider FX,
    2. Vontobel P,
    3. Hell D, et al

    . 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: a PET study with [11C]raclopride. Neuropsychopharmacology 1999;20:424–33 doi:10.1016/S0893-133X(98)00108-0 pmid:10192823

    CrossRefPubMed
63. 63.↵
    1. Barrett FS,
    2. Zhou Y,
    3. Carbonaro TM, et al

    . Human cortical serotonin 2A receptor occupancy by psilocybin measured using [11C]MDL 100,907 dynamic PET and a resting-state fMRI-based brain parcellation. Front Neuroergonomics 2022;2 doi:10.3389/fnrgo.2021.784576

    CrossRef
64. 64.↵
    1. Johansen A,
    2. Hansen HD,
    3. Svarer C, et al

    . The importance of small polar radiometabolites in molecular neuroimaging: a PET study with ¹¹C Cimbi-36 labeled in two positions. J Cereb Blood Flow Metab 2018;38:659–68 doi:10.1177/0271678X17746179 pmid:29215308

    CrossRefPubMed
65. 65.↵
    1. Madsen MK,
    2. Fisher PM,
    3. Burmester D, et al

    . Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 2019;44:1328–34 doi:10.1038/s41386-019-0324-9 pmid:30685771

    CrossRefPubMed
66. 66.↵
    1. Søndergaard A,
    2. Madsen MK,
    3. Ozenne B, et al

    . Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front Psychol 2022;13:948729 doi:10.3389/fpsyg.2022.948729 pmid:36275302

    CrossRefPubMed
67. 67.↵
    1. Savio A,
    2. Fünger S,
    3. Tahmasian M, et al

    . Resting-state networks as simultaneously measured with functional MRI and PET. J Nucl Med 2017;58:1314–17 doi:10.2967/jnumed.116.185835

    CrossRef
68. 68.↵
    1. Vollenweider FX,
    2. Leenders KL,
    3. Scharfetter C, et al

    . Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997;16:357–72 doi:10.1016/S0893-133X(96)00246-1 pmid:9109107

    CrossRefPubMedWeb of Science
69. 69.↵
    1. Gouzoulis-Mayfrank E,
    2. Schreckenberger M,
    3. Sabri O, et al

    . Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers: a double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999;20:565–81 doi:10.1016/S0893-133X(98)00089-X pmid:10327426

    CrossRefPubMed
70. 70.↵
    1. Aday JS,
    2. Heifets BD,
    3. Pratscher SD, et al

    . Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl) 2022;239:1989–2010 doi:10.1007/s00213-022-06123-7 pmid:35359159

    CrossRefPubMed
71. 71.↵
    1. McCulloch DE,
    2. Knudsen GM,
    3. Barrett FS, et al

    . Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses. Neurosci Biobehav Rev 2022;138:104689 doi:10.1016/j.neubiorev.2022.104689 pmid:35588933

    CrossRefPubMed